DreaMed Diabetes, Ltd.
http://www.dreamed-diabetes.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DreaMed Diabetes, Ltd.
Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
Reimagining The Patient Experience By Putting Practitioners At The Center
Keeping a strategic focus but pivoting to meet health care priorities on demand were qualities Align Technology’s EMEA managing director Markus Sebastian ensured were uppermost at the company during the COVID-19 pandemic.
DreaMed Receives Another FDA Clearance For AI-Powered Diabetes Software
Israeli firm DreaMed has scored a new US Food and Drug Administration clearance for its AI-based diabetes decision support system Advisor Pro. The clearance enables physicians to use the software for patients with type 1 diabetes using continuous glucose monitoring (CGMs) and blood glucose meters (BGMs).
2018 US Device Approvals: The Year Of De Novos And Digital Health
It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Medical Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Glucose Testing
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice